(R)-3-Hydroxy Midostaurin [also known as (R)-CGP-52421; (R)-CGP52421] is a minor metabolite of midostaurin, which is a multiple kinase inhibitor and an anticancer drug approved in 2017 by FDA to treat acute myeloid leukemia.

纯度：≥98%

CAS：155848-20-7